Monthly GLP-1 Obesity Shot: Berobenatide and India’s Weight Crisis Explained

Investigational medicine: Berobenatide is an experimental anti-obesity drug being developed by Pfizer. It belongs to the GLP-1 receptor agonist class, a group of medicines that mimic or activate hormone pathways linked to appetite, satiety, glucose regulation and body-weight control.

Once-monthly promise: The key reason for attention is not only weight loss but dosing convenience. Existing major obesity injectables such as semaglutide and tirzepatide are generally weekly therapies, while berobenatide is being tested for monthly maintenance dosing after initial dose escalation.

Not yet approved: A Phase 2b result is promising but not final proof. A drug normally needs larger Phase 3 trials, regulatory review, pharmacovigilance planning and post-marketing surveillance before it becomes a widely approved treatment.

Basic concept: GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone released from the gut after food intake. It helps regulate blood glucose, slows gastric emptying and increases satiety, which can reduce calorie intake.

Role in diabetes and obesity: GLP-1 receptor agonists were first important in type 2 diabetes treatment because they help improve glucose control. Later, higher-dose or modified versions became important in chronic weight management because they reduce appetite and support weight loss.

Why they are different from ordinary dieting: Lifestyle changes remain essential, but GLP-1 medicines act on biological pathways involved in hunger, satiety and metabolism. This is why many scientists now describe obesity not simply as lack of willpower, but as a chronic metabolic disease influenced by biology, environment, diet, physical activity, sleep, stress and socio-economic factors.

VESPER programme: Pfizer’s VESPER Phase 2b programme tested berobenatide in adults with obesity or overweight, including people with and without type 2 diabetes. The company says the results support Phase 3 dose planning.

Weight-loss result: In VESPER-3, monthly berobenatide showed placebo-adjusted weight loss of up to 12.3% at week 28 with the 4.8 mg monthly dose. Importantly, the trial began with weekly dosing and later shifted to monthly dosing.

Diabetes-related result: In VESPER-2, which included adults with obesity or overweight and type 2 diabetes, Pfizer reported dose-dependent reductions in body weight and HbA1c, including a 2.2% HbA1c reduction with a weekly dose at week 28 compared with 0.2% in the placebo group.

Safety signal so far: The reported side-effect profile was broadly consistent with the GLP-1 class, where nausea, vomiting and other gastrointestinal effects are common concerns. ADA Meeting News reported that in VESPER-3, 83% of treated participants had no or only mild key gastrointestinal adverse events.

Adherence: Chronic diseases require long-term treatment. If a patient needs fewer injections, continuation may become easier. This is important because stopping obesity medicines often leads to weight regain in many patients.

Healthcare convenience: Monthly dosing may reduce treatment fatigue, clinic burden and storage/administration concerns, especially for people who find weekly injections difficult.

Commercial and public health impact: If proven safe, effective and affordable, a monthly GLP-1 therapy could change the obesity-drug market. However, convenience alone is not enough. A drug must also prove long-term cardiovascular safety, metabolic benefit, tolerability and real-world effectiveness.

Wegovy: Wegovy is the brand name of semaglutide used for chronic weight management in several countries. It is a GLP-1 receptor agonist and is generally administered once weekly.

Zepbound: Zepbound is the brand name of tirzepatide for chronic weight management in the US. The FDA approved it for adults with obesity or overweight with at least one weight-related condition, in addition to reduced-calorie diet and increased physical activity.

Mounjaro: Mounjaro is also tirzepatide, but primarily associated with type 2 diabetes treatment. The same molecule can have different brand names and approved indications depending on country and regulatory approval.

Berobenatide: The distinguishing feature is the possible monthly maintenance injection. It is still investigational and cannot be treated as equivalent to approved drugs until full regulatory evaluation is completed.

Global burden: WHO says more than 1 billion people are living with obesity globally. It defines adult overweight as BMI of 25 or above and adult obesity as BMI of 30 or above.

Health risks: Obesity increases the risk of type 2 diabetes, hypertension, cardiovascular diseases, fatty liver disease, sleep apnoea, osteoarthritis, certain cancers and reduced quality of life.

Not only individual behaviour: WHO explains obesity as a multifactorial condition linked to diet, physical activity, environmental factors, psycho-social factors, genetics, medicines and disease conditions.

Rising dual burden: India faces both undernutrition and overnutrition. While undernutrition remains a concern in many regions, urbanisation, sedentary lifestyles, ultra-processed foods and high-sugar diets are increasing obesity and metabolic diseases.

NFHS-5 data: PIB has cited NFHS-5 showing that 24% of women and 23% of men in India are overweight or obese. It also notes that overweight among children under five increased from 2.1% in NFHS-4 to 3.4% in NFHS-5.

Diabetes connection: India already has a high diabetes burden. Obesity, especially abdominal obesity, worsens insulin resistance and raises the risk of type 2 diabetes. Therefore, obesity treatment is also linked to India’s non-communicable disease strategy.

Drug approval system: In India, new drugs and clinical trials are regulated through the Drugs and Cosmetics Act framework and the New Drugs and Clinical Trials Rules, 2019. CDSCO is the central drug regulatory authority involved in permissions for new drugs and clinical trials.

Clinical-trial importance: A medicine tested abroad may still need India-relevant safety, efficacy, dosage and post-marketing data because Indians may differ in body composition, genetic background, diet, diabetes profile and coexisting conditions.

Pharmacovigilance: If any such drug enters the Indian market in future, monitoring adverse effects will be important. GLP-1 drugs can cause gastrointestinal symptoms and need medical supervision, especially in people with diabetes, kidney issues, pancreatitis risk or other comorbidities.

Access and affordability: These medicines are expensive in many countries. If they remain unaffordable, only richer patients may benefit, increasing health inequality.

Medical misuse: Weight-loss drugs may be misused for cosmetic slimming without proper medical indication. This can create safety risks and distort public understanding of obesity treatment.

Lifestyle displacement risk: Drugs should not replace healthy food systems, physical activity, sleep, stress management and public-health prevention. The FDA’s approval note for tirzepatide also links drug use with reduced-calorie diet and increased physical activity.

Public health priority: India must avoid a narrow “injection-first” approach. The larger goal should be prevention, early screening, behaviour change, food-label literacy, school nutrition, urban design for physical activity and affordable clinical care.

GS2 linkage: Health governance, regulation of medicines, access to healthcare, public health schemes and state capacity.

GS3 linkage: Biotechnology, pharmaceutical innovation, clinical trials, science and technology in health, non-communicable diseases and economic impact of chronic illness.

Ethics linkage: Equity, informed consent, responsible advertising, medical ethics, patient safety and fair access to life-saving or quality-of-life-improving medicines.

Prelims linkage: GLP-1, BMI, clinical-trial phases, CDSCO, Drugs and Cosmetics Act framework, NFHS data, NCDs, diabetes and obesity terminology.

Strengthen prevention-first policy: India should prioritise healthy diets, physical activity, school-based nutrition education, front-of-pack food labelling and reduction of ultra-processed food consumption.

Ensure strict medical supervision: GLP-1 drugs should be used only under qualified medical guidance, with clear eligibility criteria and monitoring of side effects.

Generate India-specific evidence: Regulators should encourage Indian real-world studies on efficacy, safety, discontinuation, weight regain, metabolic outcomes and adverse events.

Improve NCD screening: Obesity, diabetes, hypertension and dyslipidaemia screening should be strengthened through Ayushman Arogya Mandirs and the National Programme for Prevention and Control of Non-Communicable Diseases, which focuses on screening, early diagnosis, referral, treatment and health promotion.

Make access equitable: If such medicines are approved, India must examine price regulation, insurance coverage, generic competition and rational prescribing so that treatment does not become restricted to wealthy urban groups.

Regulate advertising and online sales: Strong action is needed against unapproved, counterfeit or illegally compounded weight-loss medicines sold through online platforms.

Combine medicine with lifestyle care: Obesity management should integrate diet counselling, exercise guidance, sleep correction, mental health support and long-term follow-up.